BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics.
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer – Pharmaceutical Technology
Combination treatment of Cabometyx and Tecentriq is being investigated in cancer indications as part of a research agreement between Exelixis and Roche. Image Credit: Gorodenkoff